The Use of Bisphosphonates After Joint Arthroplasty is Associated with Lower Implant Revision Rate

Overview

Journal Knee Surg Sports Traumatol Arthrosc

Publisher Wiley

Specialties Emergency Medicine
General Surgery
Orthopedics

Date 2018 Dec 15

PMID 30547306

Citations 16

Authors

Du Hyun Ro

Heejin Jin

Jae-Young Park

Myung Chul Lee

Sungho Won

Hyuk-Soo Han

Affiliations

Soon will be listed here.

Abstract

Purpose: This study hypothesized that the use of bisphosphonates (BPs) after total joint arthroplasty (TJA) is associated with a lower implant revision rate. This study aimed (1) to investigate the association between BP use and the revision rate of TJA and (2) to determine the relationship between the medication period and the revision rate of TJA.

Methods: National Health Insurance Service data on surgeries, medications, diagnoses, and screenings of 50 million Koreans were reviewed. People who underwent TJA in the period from 2002 to 2012 were identified and followed until 2016. During that period, 331,660 patients underwent total knee arthroplasty (TKA), and 56,043 patients underwent total hip arthroplasty (THA). Among them, 8447 knee patients (2.5%) and 2851 hip patients (5.0%) required revision surgery due to aseptic loosening. Demographic data, the duration of BP medication, and comorbidities were identified. The rate of revision surgery according to BP medication was investigated. The extended Cox proportional hazard model was used to evaluate the effect of the medication period.

Results: The rate of TKA revision was 1.4% for BP users and 2.9% for BP non-users (p < 0.001). The THA revision rate was 2.8% and 5.3% for BP users and non-users, respectively (p < 0.001). The hazard ratio (HR) of revision was significantly lower in patients who took BP medication for more than one year (TKA HR = 0.472, 95% CI [0.350-0.637]; THA HR = 0.490, 95% CI [0.247-0.972]) compared to that in short-term users (less than 1 year).

Conclusions: The use of BPs after TJA was associated with a lower revision rate. The use of BPs for more than one year further reduced the risk of revision. Bisphosphonate use can be highly recommended to reduce the revision rate of TJA.

Level Of Evidence: Retrospective cohort study, Level III.

Citing Articles

The definition of atypical femoral fractures should include periprosthetic femoral fractures (PAFFs).

Makkar B, Obremskey W, Avidano R, Ott S, Basida B, Hoffer C Osteoporos Int. 2025; 36(3):539-546.

PMID: 39920401 PMC: 11905792. DOI: 10.1007/s00198-025-07401-8.

Incidence of Total Knee Arthroplasty in Older Females with Knee Osteoarthritis and Osteoporosis Treated with Denosumab Compared with Those Treated Using Bisphosphonates: A Population-Based Cohort Study.

Yu T, Wu W, Lee R, Chen I, Wang J, Wen S Life (Basel). 2025; 14(12.

PMID: 39768410 PMC: 11677198. DOI: 10.3390/life14121704.

The effects of pre-operative anti-osteoporotic use on total joint arthroplasty complications: A national database study.

Katz L, Zhang H, Ireland P, Anuszewski M, Milner J, Liu J J Orthop. 2024; 60:143-151.

PMID: 39583221 PMC: 11582541. DOI: 10.1016/j.jor.2024.11.002.

Intraoperative physician assessment during total hip arthroplasty correlates with DXA parameters.

Martin 2nd D, Lake S, Behun M, Krueger D, Binkley N, Anderson P Osteoporos Int. 2024; 35(12):2145-2151.

PMID: 39240341 DOI: 10.1007/s00198-024-07244-9.

Does Preoperative Bisphosphonate Use Impact the Risk of Periprosthetic Fracture Following Total Hip Arthroplasty?.

Busigo Torres R, Hong J, Kodali H, Poeran J, Stern B, Hayden B J Arthroplasty. 2024; 40(3):700-704.e1.

PMID: 39233096 PMC: 11810596. DOI: 10.1016/j.arth.2024.08.043.

References

Havelin L, Engesaeter L, Espehaug B, Furnes O, Lie S, Vollset S . The Norwegian Arthroplasty Register: 11 years and 73,000 arthroplasties. Acta Orthop Scand. 2000; 71(4):337-53. DOI: 10.1080/000164700317393321 . View

Stiehl J, Hamelynck K, Voorhorst P . International multi-centre survivorship analysis of mobile bearing total knee arthroplasty. Int Orthop. 2006; 30(3):190-9. PMC: 2532087. DOI: 10.1007/s00264-005-0053-z. View

Kurtz S, Ong K, Lau E, Mowat F, Halpern M . Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007; 89(4):780-5. DOI: 10.2106/JBJS.F.00222. View

Abu-Amer Y, Darwech I, Clohisy J . Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther. 2007; 9 Suppl 1:S6. PMC: 1924521. DOI: 10.1186/ar2170. View

Drake M, Clarke B, Khosla S . Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83(9):1032-45. PMC: 2667901. DOI: 10.4065/83.9.1032. View

Thillemann T, Pedersen A, Mehnert F, Johnsen S, Soballe K . Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone. 2010; 46(4):946-51. DOI: 10.1016/j.bone.2010.01.377. View

Carano A, Teitelbaum S, Konsek J, Schlesinger P, Blair H . Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest. 1990; 85(2):456-61. PMC: 296445. DOI: 10.1172/JCI114459. View

Lin T, Yan S, Cai X, Ying Z . Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials. Osteoporos Int. 2011; 23(6):1823-34. DOI: 10.1007/s00198-011-1797-5. View

Skoldenberg O, Salemyr M, Boden H, Ahl T, Adolphson P . The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial. J Bone Joint Surg Am. 2011; 93(20):1857-64. DOI: 10.2106/JBJS.J.01646. View

10.

Prieto-Alhambra D, Javaid M, Judge A, Murray D, Carr A, Cooper C . Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ. 2011; 343:d7222. PMC: 3232250. DOI: 10.1136/bmj.d7222. View

11.

Noordin S, Masri B . Periprosthetic osteolysis: genetics, mechanisms and potential therapeutic interventions. Can J Surg. 2012; 55(6):408-17. PMC: 3506691. DOI: 10.1503/cjs.003711. View

12.

Vasso M, Beaufils P, Cerciello S, Panni A . Bone loss following knee arthroplasty: potential treatment options. Arch Orthop Trauma Surg. 2014; 134(4):543-53. DOI: 10.1007/s00402-014-1941-8. View

13.

Prieto-Alhambra D, Lalmohamed A, Abrahamsen B, Arden N, de Boer A, Vestergaard P . Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort. Arthritis Rheumatol. 2014; 66(11):3233-40. DOI: 10.1002/art.38789. View

14.

Khatod M, Inacio M, Dell R, Bini S, Paxton E, Namba R . Association of Bisphosphonate Use and Risk of Revision After THA: Outcomes From a US Total Joint Replacement Registry. Clin Orthop Relat Res. 2015; 473(11):3412-20. PMC: 4586196. DOI: 10.1007/s11999-015-4263-4. View

15.

Patel A, Pavlou G, Mujica-Mota R, Toms A . The epidemiology of revision total knee and hip arthroplasty in England and Wales: a comparative analysis with projections for the United States. A study using the National Joint Registry dataset. Bone Joint J. 2015; 97-B(8):1076-81. DOI: 10.1302/0301-620X.97B8.35170. View

16.

Teng S, Yi C, Krettek C, Jagodzinski M . Bisphosphonate Use and Risk of Implant Revision after Total Hip/Knee Arthroplasty: A Meta-Analysis of Observational Studies. PLoS One. 2015; 10(10):e0139927. PMC: 4596810. DOI: 10.1371/journal.pone.0139927. View

17.

Namba R, Inacio M, Cheetham T, Dell R, Paxton E, Khatod M . Lower Total Knee Arthroplasty Revision Risk Associated With Bisphosphonate Use, Even in Patients With Normal Bone Density. J Arthroplasty. 2015; 31(2):537-41. DOI: 10.1016/j.arth.2015.09.005. View

18.

Singh J, Schleck C, Harmsen W, Jacob A, Warner D, Lewallen D . Current tobacco use is associated with higher rates of implant revision and deep infection after total hip or knee arthroplasty: a prospective cohort study. BMC Med. 2015; 13:283. PMC: 4653911. DOI: 10.1186/s12916-015-0523-0. View

19.

Jasper L, Jones C, Mollins J, Pohar S, Beaupre L . Risk factors for revision of total knee arthroplasty: a scoping review. BMC Musculoskelet Disord. 2016; 17:182. PMC: 4845333. DOI: 10.1186/s12891-016-1025-8. View

20.

Lim C, Goodman S, Huddleston 3rd J, Harris A, Bhowmick S, Maloney W . Smoking is associated with earlier time to revision of total knee arthroplasty. Knee. 2017; 24(5):1182-1186. DOI: 10.1016/j.knee.2017.05.014. View